## an Academic Medical Center

Registration: 4557



Ravitej Goteti, MD (rgoteti1@hfhs.org); Lea Monday PharmD, MD; Charlie Makowski PharmD; Allison Weinmann MBBS, FRACP

### Background

- OPAT program is a complex process with multidisciplinary involvement and is error prone
- Re-admission rates have been reported to be between 15%-25%.
- Impact of COVID-19 pandemic on healthcare systems:
  - Decreased # of elective surgeries during surges
  - Limited availability of resources, including home health services and skilled nursing facilities
- This study was designed to see if COVID-19 has impacted our OPAT care, particularly with hospital re-admissions and ID clinic follow up

#### Methods N = 316Comparison Demographics Oct – Dec Infection source Patients discharged 2019 Antimicrobials from Henry Ford Discharge location Oct – Dec Hospital with OPAT ID follow-up Readmission N = 263

Figure 1:Study Design

Retrospective observational cohort study

- Variables between groups were compared using Chi-squared or Wilcoxon Rank Sum (Mann-Whitney U) test as appropriate for non-parametric data
- p<0.05 considered statistically significant.</li>

#### **Primary Outcomes**

- 1. 30 day re-admission rates between the two cohorts
- 2. ID clinic follow up between the two cohorts

## **Secondary Outcomes**

Identify differences in the two cohorts for

- 1. Hospital Length of Stay (LoS)
- 2. Discharge location (home versus facility)
- 3. Infection source and antimicrobial therapy




Table 2: Outcomes – ID follow up and hospital utilization						
	Total	Pre-COVID-19	COVID-19	p-		
	(n=579)	(n=316)	(n=263)	value		
ID clinic visit within 4 weeks,	260 (44.9)	136 (43.0)	124 (47.1)	0.322		
n (%)						
Days to Hospital Utilization,	11 (5-19)	11 (5 – 18.5)	10 (4 –	0.675		
median (IQR)			18.5)			
30 day Hospital Utilization, n	189 (32.6)	107 (33.9)	82 (31.2)	0.49		
(%)						

# Table 3: Hospital Utilization - Readmissions and Emergency Room Visits

	Total (n=189)	Pre COVID-19 (n=107)	COVID-19 (n=82)	p-value	
Any Emergency Room Visit, n	75 (13.0)	36 (11.4)	39 (14.8)	0.220	
Any 30-Day Readmission, n	114 (19.7)	71 (22.5)	43 (16.3)	0.065	
OPAT-Related ER Visit, n	18 (3.1)	10 (3.2)	8 (3)	0.932	
OPAT-Related re-admission, n	30 (5.2)	17 (5.4)	13 (4.9)	0.813	

Reasons for OPAT related re-admissions: line malfunction, adverse drug reaction, laboratory abnormalities, lack of source control or worsening infection

Most common reasons for Non-OPAT related visits: CHF, Bleeding, COPD exacerbation, CVA and liver cirrhosis




Figure 2: Infection Sources among OPAT patients

**Table 4: Impact of COVID-19 on OPAT Antimicrobial Prescribing** Pre-COVID- COVID-19 **Total Antimicrobial Class** (n=579)(n=263) value (n=316)12 (4.6) 0.646 **Antifungals** 24 (4.1) 12 (3.8) **Antivirals** 4 (0.7) 3 (0.9) 1 (0.4) 0.410 0.807 Aminoglycoside 5 (0.9) 3 (0.9) 2 (0.8) 0.086 **BL-BLI** combination 24 (4.1) 9 (2.8) 15 (5.7) 124 (21.4) 69 (21.8) 55 (20.9) 0.788 Carbapenem 251 (43.4) 128 (40.5) Cephalosporin 123 (46.8) 0.130 **Daptomycin** 151 (26.1) 92 (29.1) 0.068 **Extended Spectrum B-Lactam** 21 (3.6) 14 (4.4) Penicillin 44 (7.6) 27 (8.5) 17 (6.5) 0.347 1 (0.2) 0(0.0)1 (0.4) 0.454 Quinolone 5 (1.9) 6 (1.0) 1 (0.3) 0.097 **Tetracyclines** 56 (9.7) 23 (7.3) 33 (12.5) **0.033** Vancomycin

#### Conclusion

- 30-day readmission or ID follow up visit after discharge, did not differ in the pre-COVID-19 and COVID-19 cohorts.
- There was a statistically significant increase in OPAT patients being discharged to home during the pandemic
- Overall post-discharge ID clinic follow was only 44%
  - ID follow up post discharge for OPAT patients is associated with decreased hospital re-admission rates.

## Quality improvement initiatives

 Modification of Infectious Diseases OPAT documentation, to include scheduled ID clinic appointment within 2 weeks of discharge

